Generics

Innovative 1

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-047 manufacturers

1 products found

Filters

Filters

Filters , active

Country of origin : China

Clear all

1 products found

pp-047

Tablets

Dossier type
CTD
Dossier status
Under development
Country of origin
China
Comments
Indication: HER2-positive metastatic and locally advanced breast cancer after prior therapy; HER2-altered including HER2 exon20-mutated NSCLC. Clinical stage: Marketed in China since 2018 for HER2+ MBC; Phase III/II ongoing in breast cancer and NSCLC. Modality: Oral irreversible pan-HER small molecule TKI. Mechanism: Inhibits EGFR/HER2/HER4 signaling. Route / form: Oral, typically administered once daily in fixed dose, commonly in combination with capecitabine or taxane-based chemotherapy. Differentiation: First-in-class in China; strong efficacy vs lapatinib and CNS activity.
Manufacturer #17216

Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.

Manufacturer usually replies in 12 days

Want to see all 1 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.